Captor Therapeutics S.A. (CTX) - Net Assets
Based on the latest financial reports, Captor Therapeutics S.A. (CTX) has net assets worth zł33.27 Million PLN (≈ $9.16 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł44.54 Million ≈ $12.26 Million USD) and total liabilities (zł11.27 Million ≈ $3.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CTX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł33.27 Million |
| % of Total Assets | 74.7% |
| Annual Growth Rate | 139.16% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 863.52 |
Captor Therapeutics S.A. - Net Assets Trend (2017–2024)
This chart illustrates how Captor Therapeutics S.A.'s net assets have evolved over time, based on quarterly financial data. Also explore Captor Therapeutics S.A. total assets for the complete picture of this company's asset base.
Annual Net Assets for Captor Therapeutics S.A. (2017–2024)
The table below shows the annual net assets of Captor Therapeutics S.A. from 2017 to 2024. For live valuation and market cap data, see CTX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł64.47 Million ≈ $17.74 Million |
-6.86% |
| 2023-12-31 | zł69.22 Million ≈ $19.05 Million |
-28.14% |
| 2022-12-31 | zł96.32 Million ≈ $26.51 Million |
-22.45% |
| 2021-12-31 | zł124.20 Million ≈ $34.18 Million |
+12470.62% |
| 2020-12-31 | zł-1.00 Million ≈ $-276.32K |
-123.47% |
| 2019-12-31 | zł4.28 Million ≈ $1.18 Million |
+24.69% |
| 2018-12-31 | zł3.43 Million ≈ $944.26K |
+2282.64% |
| 2017-12-31 | zł144.00K ≈ $39.63K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Captor Therapeutics S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20289700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł550.00K | 0.85% |
| Other Comprehensive Income | zł26.54 Million | 41.17% |
| Other Components | zł240.49 Million | 373.01% |
| Total Equity | zł64.47 Million | 100.00% |
Captor Therapeutics S.A. Competitors by Market Cap
The table below lists competitors of Captor Therapeutics S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Spir Group ASA
OL:SPIR
|
$119.48 Million |
|
After You Public Company Limited
BK:AU
|
$119.48 Million |
|
Nicola Mining Inc
V:NIM
|
$119.50 Million |
|
Cornerstone OnDemand Inc
F:8CO
|
$119.51 Million |
|
China Automotive Systems Inc
F:RYV
|
$119.38 Million |
|
Tonlin Department Store Co Ltd
TW:2910
|
$119.36 Million |
|
Tempore Properties SOCIMI SAU
MC:YTEM
|
$119.34 Million |
|
Newcore Gold Ltd
V:NCAU
|
$119.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Captor Therapeutics S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 69,220,000 to 64,474,000, a change of -4,746,000 (-6.9%).
- Net loss of 38,426,000 reduced equity.
- New share issuances of 3,000 increased equity.
- Other comprehensive income increased equity by 1,984,000.
- Other factors increased equity by 31,693,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-38.43 Million | -59.6% |
| Share Issuances | zł3.00K | +0.0% |
| Other Comprehensive Income | zł1.98 Million | +3.08% |
| Other Changes | zł31.69 Million | +49.16% |
| Total Change | zł- | -6.86% |
Book Value vs Market Value Analysis
This analysis compares Captor Therapeutics S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1782.01x to 5.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | zł0.04 | zł78.80 | x |
| 2018-12-31 | zł1.05 | zł78.80 | x |
| 2019-12-31 | zł1.31 | zł78.80 | x |
| 2020-12-31 | zł-0.31 | zł78.80 | x |
| 2021-12-31 | zł30.09 | zł78.80 | x |
| 2022-12-31 | zł23.11 | zł78.80 | x |
| 2023-12-31 | zł14.90 | zł78.80 | x |
| 2024-12-31 | zł13.84 | zł78.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Captor Therapeutics S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -242.82%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.36x
- Recent ROE (-59.60%) is above the historical average (-85.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -125.00% | -37.97% | 0.09x | 35.58x | zł-194.40K |
| 2018 | -128.88% | -27637.50% | 0.00x | 5.26x | zł-4.77 Million |
| 2019 | -204.21% | 0.00% | 0.00x | 5.91x | zł-9.16 Million |
| 2020 | 0.00% | -900.07% | 0.06x | 0.00x | zł-12.99 Million |
| 2021 | -26.23% | -817.16% | 0.03x | 1.16x | zł-44.99 Million |
| 2022 | -37.26% | -391.94% | 0.08x | 1.17x | zł-45.53 Million |
| 2023 | -101.97% | -534.69% | 0.14x | 1.41x | zł-77.51 Million |
| 2024 | -59.60% | -242.82% | 0.18x | 1.36x | zł-44.87 Million |
Industry Comparison
This section compares Captor Therapeutics S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $187,326,215
- Average return on equity (ROE) among peers: -5.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Captor Therapeutics S.A. (CTX) | zł33.27 Million | -125.00% | 0.34x | $119.47 Million |
| Bioton S.A. (BIO) | $1.38 Billion | -6.06% | 0.46x | $98.54 Million |
| Mabion S.A. (MAB) | $127.64 Million | -3.60% | 0.52x | $33.23 Million |
| Molecure S.A. (MOC) | $15.43 Million | -3.62% | 0.07x | $31.98 Million |
| Nanogroup SA (NNG) | $7.78 Million | -10.77% | 1.47x | $22.04 Million |
| Pharmena S.A. (PHR) | $-6.79 Million | 0.00% | 0.00x | $10.02 Million |
| PolTREG S.A. (PTG) | $12.83 Million | -6.84% | 0.27x | $21.82 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $39.49 Million | -33.10% | 0.20x | $7.58 Million |
| Ryvu Therapeutics SA (RVU) | $46.88 Million | 13.37% | 0.39x | $152.71 Million |
| Synthaverse S.A. (SVE) | $57.81 Million | 1.02% | 1.09x | $68.82 Million |
About Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. … Read more